YESBANK.NSEYes Bank Ltd

BENGALURU: India’s economic growth outlook is broadly unchanged despite the U.S.-Israeli war with Iran, according to a Reuters poll of economists who warned that data won’t capture an already-notable hit to the country’s vast informal sector. The extent of the stress is hard to gauge due to limited real-time figures on fuel costs, jobs, demand and small businesses, although anecdotal evidence points to early strain in the shadow economy, which has previously accounted for almost half of official GDP readings. In cities, where roughly 60% of GDP is generated, many restaurants and hotels have been forced to reduce operating hours, cut menus or switch to using alternative fuels like firewood as the Middle East conflict disrupts supplies of liquefied petroleum gas. Although India’s new GDP series has increased data inputs in an attempt to better capture the informal economy, economists say more needs to be done to get a clear picture. India proposes ‘economic stabilisation fund’ to tackle global headwinds India’s gross domestic product is expected to grow 6.7% this fiscal year, according to an April 20-27 Reuters poll of 54 economists, in line with March’s forecast.

Max Estates Limited has expanded its financial backing for subsidiary Max Square Limited by issuing an additional Rs 100 crore corporate guarantee on April 27, 2026. This takes its total guarantee commitment to Rs 350 crore. The guarantee supports existing loans from ICICI Bank and Yes Bank, aimed at funding a commercial real estate project in Noida.

Max Estates Limited has expanded its financial backing for subsidiary Max Square Limited by issuing an additional Rs 100 crore corporate guarantee on April 27, 2026. This takes its total guarantee commitment to Rs 350 crore. The guarantee supports existing loans from ICICI Bank and Yes Bank, aimed at funding a commercial real estate project in Noida.

In this briefing: ICICI Life (IPRU IN) Vs ICICI GIC (ICICIGI IN): Life Vs General Insurance Spread Signals Trade US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage 1. ICICI Life (IPRU IN) Vs ICICI GIC (ICICIGI IN): Life Vs General Insurance Spread Signals Trade Context: The ICICI Lombard General Insurance (ICICIGI IN) vs. ICICI Prudential Life (IPRU IN) price-ratio has deviated two standard deviations from its one-year average, presenting a potential relative value opportunity. Highlight: Going long ICICI Prudential Life Insurance (IPRU IN) and short ICICI Lombard General Insurance Company (ICICIGI IN) targets a 6% return. Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play. 2.

In this briefing: ICICI Life (IPRU IN) Vs ICICI GIC (ICICIGI IN): Life Vs General Insurance Spread Signals Trade US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage 1. ICICI Life (IPRU IN) Vs ICICI GIC (ICICIGI IN): Life Vs General Insurance Spread Signals Trade Context: The ICICI Lombard General Insurance (ICICIGI IN) vs. ICICI Prudential Life (IPRU IN) price-ratio has deviated two standard deviations from its one-year average, presenting a potential relative value opportunity. Highlight: Going long ICICI Prudential Life Insurance (IPRU IN) and short ICICI Lombard General Insurance Company (ICICIGI IN) targets a 6% return. Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play. 2.

In this briefing: US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 1. US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! On April 2, 2026, a bipartisan group of US lawmakers introduced H.R. 8170, the Multilateral Alignment of Technology Controls on Hardware Act, or the MATCH Act. Three weeks later, on April 22, the House Foreign Affairs Committee advanced it in what lawmakers called ”the largest significant export control mark-up in the history of Congress.” If enacted, the immersion DUV ban will deal a serious blow to China's semiconductor ambitions in the medium term. It will also greatly accelerate Chinese efforts to develop their own... 2. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 3.

In this briefing: US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 1. US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! On April 2, 2026, a bipartisan group of US lawmakers introduced H.R. 8170, the Multilateral Alignment of Technology Controls on Hardware Act, or the MATCH Act. Three weeks later, on April 22, the House Foreign Affairs Committee advanced it in what lawmakers called ”the largest significant export control mark-up in the history of Congress.” If enacted, the immersion DUV ban will deal a serious blow to China's semiconductor ambitions in the medium term. It will also greatly accelerate Chinese efforts to develop their own... 2. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 3.

In this briefing: Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 1. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 2. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev.

In this briefing: Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 1. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 2. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev.